IBB vs. CNCR

Last updated Apr 2, 2026

Compare and contrast key facts about iShares Nasdaq Biotechnology ETF (IBB) and Loncar Cancer Immunotherapy ETF (CNCR).

IBB and CNCR are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IBB is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology Index. It was launched on Feb 5, 2001. CNCR is a passively managed fund by Exchange Traded Concepts that tracks the performance of the Loncar Cancer Immunotherapy Index. It was launched on Oct 13, 2015. Both IBB and CNCR are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

IBB vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Nasdaq Biotechnology ETF (IBB) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

IBB vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
IBB iShares Nasdaq Biotechnology ETF	-2.70%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

Returns By Period

IBB

• 1D: 0.76%
• 1M: -2.11%
• YTD: 0.88%
• 6M: 14.77%
• 1Y: 37.04%
• 3Y*: 9.92%
• 5Y*: 2.62%
• 10Y*: 6.92%

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IBB vs. CNCR - Expense Ratio Comparison

IBB has a 0.47% expense ratio, which is lower than CNCR's 0.79% expense ratio.

CNCR

Loncar Cancer Immunotherapy ETF

IBB

iShares Nasdaq Biotechnology ETF

Return for Risk

IBB vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IBB

IBB Risk / Return Rank: 81
IBB Sharpe Ratio Rank: 80
IBB Sortino Ratio Rank: 81
IBB Omega Ratio Rank: 73
IBB Calmar Ratio Rank: 88
IBB Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IBB vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq Biotechnology ETF (IBB) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IBB	CNCR	Difference
Sharpe ratio Return per unit of total volatility	1.56	—	—
Sortino ratio Return per unit of downside risk	2.16	—	—
Omega ratio Gain probability vs. loss probability	1.28	—	—
Calmar ratio Return relative to maximum drawdown	2.86	—	—
Martin ratio Return relative to average drawdown	10.20	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	IBB	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.56	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.12	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.30	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.26	—	—

Dividends

IBB vs. CNCR - Dividend Comparison

IBB's dividend yield for the trailing twelve months is around 0.23%, while CNCR has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
IBB iShares Nasdaq Biotechnology ETF	0.23%	0.23%	0.29%	0.26%	0.31%	0.21%	0.21%	0.33%	0.20%	0.30%	0.19%	0.03%
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

IBB vs. CNCR - Drawdown Comparison

The maximum IBB drawdown since its inception was -62.85%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for IBB and CNCR.

Drawdown Indicators

	IBB	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-62.85%	0.00%	-62.85%
Max Drawdown (1Y) Largest decline over 1 year	-11.65%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-39.82%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-39.82%	—	—
Current Drawdown Current decline from peak	-4.16%	0.00%	-4.16%
Average Drawdown Average peak-to-trough decline	-21.30%	0.00%	-21.30%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.27%	—	—

Volatility

Volatility by Period

	IBB	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.38%	—	—
Volatility (6M) Calculated over the trailing 6-month period	14.50%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	24.01%	0.00%	+24.01%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	21.87%	0.00%	+21.87%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	23.37%	0.00%	+23.37%